sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Summary of Product Characteristics last updated on the eMC: 06/11/2009
SPC Brochlor eye ointment


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Brochlor 1.0% w/w Eye Ointment


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Chloramphenicol 1.0% w/w

For excipients see 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Eye ointment, that is smooth and translucent


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Treatment of acute bacterial conjunctivitis.


Go to top of the page
4.2 Posology and method of administration

For ocular use.

The recommended dosage for adults, including the elderly and children aged 2 years and over is a small amount of ointment to be applied to the affected eye, either at night if eye drops are used during the day, or 3-4 times daily if the eye ointment is used alone.

Treatment should continue for 5 days, even if symptoms improve.


Go to top of the page
4.3 Contraindications

Chloramphenicol eye ointment should not be administered to patients hypersensitive to chloramphenicol or any other ingredients in the formulation, or given to those with a known personal or family history of blood dyscrasias including aplastic anaemia.


Go to top of the page
4.4 Special warnings and precautions for use

Prolonged use of chloramphenicol eye ointment should be avoided as it may increase the likelihood of sensitisation and emergence of resistant organisms.

Do not use for more than 5 days without consulting a doctor.

Medical advice should be sought if there is no improvement in the condition after 2 days or if symptoms worsen at any time.

Patients should be referred to their doctor if any of the following apply:

• Disturbed vision

• Severe pain within the eye

• Photophobia

• Eye inflammation associated with a rash on the scalp or face

• The eye looks cloudy

• The pupil looks unusual

• Suspected foreign body in the eye

Patients should also be referred to their doctor if any of the following in his/her medical history apply:

• Previous conjunctivitis in the recent past

• Glaucoma

• Dry eye syndrome

• Eye surgery or laser treatment in the last 6 months

• Eye injury

• Current use of other eye drops or eye ointment

If you wear contact lenses, seek advice either from your contact lens practitioner (optician, optometrist) or doctor before you use this product. You should not wear your contact lenses during the course of treatment. If you wear soft contact lenses do not start wearing them for at least 24 hours after you have finished using the eye ointment.

The labels will state:

• If symptoms do not improve within 48 hours talk to your doctor.

• Seek further immediate medical advice at any time if symptoms worsen.

• Discard any remaining eye ointment after the five day course of treatment.

• (carton) Do not use if you are allergic to chloramphenicol or any of the ingredients.

• (carton) You should not use this ointment if you are allergic to chloramphenicol or any of the other ingredients.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

The concomitant administration of chloramphenicol with other drugs liable to depress bone marrow function should be avoided.


Go to top of the page
4.6 Pregnancy and lactation

The safety of Chloramphenicol Eye Ointment during pregnancy and lactation has not been established.

Chloramphenicol may be absorbed systemically following the use of eye ointment and may cross the placenta and appear in breast milk. Therefore this product is not recommended for use during pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

Chloramphenicol Eye Ointment may cause transient blurring of vision. Patients should be warned not to drive or operate hazardous machinery unless vision is clear.


Go to top of the page
4.8 Undesirable effects

Ointment may cause irritation when applied, such as burning stinging, itching, irritation and inflammation of the skin.

Bone marrow depression, including, irreversible and fatal aplastic anaemia has been reported following topical use of chloramphenicol. Whilst the hazard is a rare one, it should be borne in mind when assessing the benefits expected from the use of this compound.


Go to top of the page
4.9 Overdose

Not applicable.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Chloramphenicol is a broad spectrum antibiotic with bacteriostatic activity and is effective against a wide range of Gram-negative and Gram-positive organisms, including Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus viridans, Moraxella species and Enterobacteriaceae, the main pathogens responsible for acute bacterial conjunctivitis. Chloramphenicol exerts its antibacterial effect by reversibly binding to bacterial ribosomes thereby inhibiting bacterial protein synthesis.


Go to top of the page
5.2 Pharmacokinetic properties

When chloramphenicol ointment is applied to the eye the drug is detectable in tears and aqueous humour. In one study, 1% w/w ointment gave chloramphenicol levels in tears and aqueous humour which exceeded the minimum bacteriostatic concentration (approximately 1 microgram/ml) for up to 2-4 hours.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Liquid paraffin,

Plastibase 50W.


Go to top of the page
6.2 Incompatibilities

Not known.


Go to top of the page
6.3 Shelf life

48 months.

Although the shelf life once opened is 28 days, patients should be advised to discard the contents 5 days after opening.


Go to top of the page
6.4 Special precautions for storage

Store below 25oC.


Go to top of the page
6.5 Nature and contents of container

Brochlor 1% w/w Eye Ointment is available in a 4g laminated tube.


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

sanofi-aventis

One Onslow Street

Guildford

Surrey

GU1 4YS


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 04425/0367


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

July 2004


Go to top of the page
10. DATE OF REVISION OF THE TEXT

25 September 2009


Go to top of the page
LEGAL CLASSIFICATION

P



More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/19854/SPC/Brochlor eye ointment/

Active Ingredients/Generics

 
   chloramphenicol


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk